DEPLOYDatabase

Incident · Regulatory action

FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device

The FDA granted De Novo classification to Vitestro Aletta, the first standalone robotic device that can draw blood from a patient arm without hands-on operator intervention. Clinical data showed Aletta achieves successful blood draw rates comparable to or better than trained human phlebotomists across a broad range of patients. The device includes onboard sensors that can pause the procedure and alert a supervising phlebotomist if unsafe conditions are detected.

Occurred 2026-08-19 · Vitestro · Investigated by FDA

How to read this record

Incident records on DEPLOY are compiled from public sources (regulatory filings, news reports, and operator disclosures) and reflect what has been reported and tracked to date. They are not legal findings, determinations of fault, or safety ratings, and may be updated as new information is verified. See the sources below for the underlying references.
Track FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device

Machine-readable surfaces

Sources (1)

  1. U.S. Food and Drug Administration · https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device · 2026-08-19

Status history

  • Active · 2026-08-27 · agent:recon

Common questions

What happened in FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device?
The FDA granted De Novo classification to Vitestro Aletta, the first standalone robotic device that can draw blood from a patient arm without hands-on operator intervention. Clinical data showed Aletta achieves successful blood draw rates comparable to or better than trained human phlebotomists across a broad range of patients. The device includes onboard sensors that can pause the procedure and alert a supervising phlebotomist if unsafe conditions are detected.
When did this incident occur?
The incident is recorded as occurring on August 19, 2026 on the DEPLOY registry. The date reflects the underlying real-world event, not the registry record's creation date.
Who was involved in FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device?
The incident is recorded as involving Vitestro on the DEPLOY registry. No specific robot model is linked to this incident in the registry.
Has anyone responded to FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device?
No responses to this incident are recorded on the DEPLOY registry. Operators, manufacturers, or affected parties can submit responses to the editorial team; absence is not a guarantee no response was issued.
What is the current status of FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device?
This incident is an active record on the DEPLOY registry; no retraction or correction has been issued.
Methodology: Unreviewed · 1 source (1 primary) · last reviewed 2026-08-27

Verification posture

Unreviewed

Low confidence

Review state

Stable

Last reviewed 2026-08-27

Sources by quality tier

1
primary-fda-database
FDA database

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device.

Deploy Watch

Track this incident.

We notify you when the regulator updates the record, the remedy status changes, or a related incident surfaces.

Canonical ID c766aef1-c6ef-4b93-8459-f4a9ecc72c7e